Sino Biopharmaceutical Announces Breakthrough Phase III Results for Bepirovirsen in Chronic Hepatitis B – Potential Share Price Catalyst

Sino Biopharmaceutical Limited (HKEX: 1177) has released a voluntary announcement with highly significant, potentially price-sensitive updates regarding its investigational hepatitis B treatment, bepirovirsen. The news includes positive Phase III trial data, regulatory review status, and details of a strategic partnership with GSK plc, all of which could materially affect the company’s share value.

Key Points from the Announcement

• Positive Phase III Results:
  • Pivotal data from two global Phase III clinical trials (B-Well 1 and B-Well 2) for bepirovirsen in chronic hepatitis B (CHB) were simultaneously published in the New England Journal of Medicine and presented at EASL 2026.
  • The trials demonstrated statistically significant and clinically meaningful functional cure rates for bepirovirsen vs. placebo.
  • Among patients with baseline HBsAg ≤3000 IU/ml, the functional cure rate at Week 72 was 19% (233 of 1,220) vs. 0% in placebo. For those with ≤1000 IU/ml, the functional cure rate rose to 26% (200 of 768), with the Chinese subgroup achieving up to 35%.
  • Functional cure is defined as undetectable HBsAg and HBV DNA for at least 6 months post-treatment cessation, a major improvement over the current standard of care (which achieves functional cure in less than 1% of patients).
  • Exploratory endpoints showed 49% of bepirovirsen recipients reached qHBsAg ≤100 IU/mL one year after treatment, associated with better immune control and outcomes.
  • Sustained HBV DNA suppression (
• Safety Profile:
  • Acceptable safety and tolerability, consistent with previous studies. Most frequent adverse events were injection site erythema, local pain, and temporary increases in liver enzymes.
• Regulatory Status:
  • Bepirovirsen is under review by regulatory authorities in China (Breakthrough Therapy and Priority Review), the US (Priority Review, Breakthrough Therapy, Fast Track), Europe, and Japan (SENKU designation).
  • GSK expects a regulatory decision from China’s NMPA in the first half of 2027, with launch preparations underway.
• Strategic Partnership with GSK:
  • In May 2026, Sino Biopharmaceutical’s subsidiary CTTQ entered into an exclusive strategic collaboration with GSK for the China launch of bepirovirsen.
  • CTTQ will handle importation, distribution, hospital access, and promotional/non-promotional activities. Revenue from China sales will be recognized by CTTQ.
  • GSK retains marketing authorization, regulatory, quality, pharmacovigilance, and global medical strategy responsibilities.
  • Both parties will explore broader R&D collaboration outside China, potentially expanding future revenue streams and partnerships.
• Market Opportunity:
  • CHB affects over 240 million people globally, including 75 million in China, causing 1.1 million annual deaths and accounting for 56% of liver cancer cases worldwide.
  • Bepirovirsen targets a large patient population that currently requires lifelong therapy, with functional cure as a critical unmet need.

Investor Impact and Price Sensitivity

• The positive efficacy and safety results for bepirovirsen represent a potential paradigm shift in hepatitis B treatment, raising the likelihood of regulatory approval and commercial success.
• The close proximity of a regulatory decision and anticipated launch in China (first half of 2027) could accelerate revenue growth and market share, especially given the size of the Chinese CHB population.
• Exclusive partnership with GSK ensures robust commercialization capability and revenue recognition for Sino Biopharmaceutical (via CTTQ) in China. This arrangement is likely to strengthen future earnings visibility.
• Further collaboration with GSK on R&D assets could unlock additional value streams beyond China.
• If bepirovirsen is approved, it would be the first therapy to deliver functional cure rates far above current treatments, addressing a major clinical and commercial gap.

Conclusion

These developments are highly newsworthy and may materially move the share price of Sino Biopharmaceutical Limited, due to the potential for first-in-class approval, major commercial opportunity, and strategic partnership with GSK. Investors should monitor regulatory milestones and launch progress closely.

Disclaimer: The information above is for reference and informational purposes only and does not constitute investment advice. Investors should conduct their own research and consult professionals before making investment decisions. Clinical and regulatory outcomes may differ from projections.

中國生物製藥公布Bepirovirsen治療乙型肝炎三期臨床數據突破性成果－有潛力推動股價

中國生物製藥有限公司（港交所：1177）公布自願公告，內容涉及其乙型肝炎新藥bepirovirsen的重大、具價格敏感性進展，包括三期臨床試驗正面結果、監管審查進度及與GSK戰略合作詳情，均可能對公司股價造成重大影響。

報告重點

• 三期臨床試驗結果突破：
  • bepirovirsen於全球兩項三期臨床B-Well 1及B-Well 2試驗，數據同時刊登於新英格蘭醫學雜誌及2026年歐洲肝臟學會（EASL）會議公布。
  • 試驗顯示bepirovirsen組功能性治癒率與安慰劑組對比有統計及臨床顯著差異。
  • 基線HBsAg ≤3000 IU/ml患者，72週功能性治癒率達19%（1,220人中233人），安慰劑組為0%；基線≤1000 IU/ml患者功能性治癒率26%（768人中200人），中國子群達35%。
  • 功能性治癒定義為停止所有治療後至少6個月HBsAg及HBV DNA均不可檢出，遠高於現有療法（治癒率不足1%）。
  • 探索性指標顯示49%受試者治療一年後qHBsAg降至≤100 IU/mL，與免疫控制及預後改善相關。
  • 23%（所有受試者）及31%（基線≤1000 IU/ml）受試者72週達到HBV DNA持續低於定量下限。
• 安全性：
  • 安全性及耐受性良好，與過往研究一致。最常見副作用為注射部位紅斑、局部疼痛及肝酶短暫升高。
• 監管狀況：
  • bepirovirsen正接受中國（突破性療法及優先審查）、美國（優先審查、突破性療法、快速通道）、歐洲及日本（SENKU指定）監管審查。
  • GSK預計2027年上半年獲中國藥監局審批決定，並已展開上市準備。
• 與GSK戰略合作：
  • 2026年5月，子公司正大天晴與GSK簽署中國上市獨家戰略合作協議。
  • 正大天晴負責進口、分銷、醫院進入、市場推廣及相關活動，中國銷售收入將由正大天晴確認。
  • GSK保留產品上市許可、監管、質量、藥物警戒及全球醫學策略。
  • 雙方將探索中國以外創新研發資產更廣泛合作，擴展未來收入及合作機遇。
• 市場機會：
  • 全球乙型肝炎患者逾2.4億人，中國約7,500萬，每年死亡1.1百萬，佔全球肝癌病例56%。
  • bepirovirsen針對需終身治療的龐大患者群，功能性治癒成為關鍵未被滿足需求。

投資者影響及價格敏感點

• bepirovirsen正面療效及安全性結果是乙肝治療格局重大轉變，增加獲批及商業成功機會。
• 中國監管決策臨近，預計2027年上市，有望加速收入增長及市場份額。
• 專屬GSK合作保證中國商業化能力及收入確定性，對未來盈利預期具正面作用。
• 與GSK進一步研發合作有望解鎖中國以外新價值。
• 若獲批，將成首款大幅提升功能性治癒率療法，填補巨大臨床及商業空白。

總結

上述進展極具新聞價值，可能顯著推動中國生物製藥股價，因其首創療法獲批機會、巨大商業潛力及與GSK戰略合作。投資者應密切關注監管進展及上市步伐。

免責聲明：以上資料僅供參考及資訊用途，並不構成投資建議。投資者應自行研究及諮詢專業人士作出決策。臨床及監管結果或與預期不同。

View SBP GROUP Historical chart here